Alison Y. Zhang - Concepedia

Author

Alison Y. Zhang

The University of Sydney ORCID

Also Known As

A Y Zhang, A. Y. Zhang, A. Zhang, A.Y. Zhang, Aiwen Zhang, Alison Y Zhang, Alison Y. Zhang, Alison Zhang, Sonia Yip

Publications

5.2K

Citations

H-Index

Concepts

All Affiliations

The University of Sydney Chris O’Brien Lifehouse Peter MacCallum Cancer Centre Monash University Garvan Institute of Medical Research

About

Alison Y. Zhang is an author at The University of Sydney specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	12	3K
2	Pharmacology	4	5	2.3K
3	Cancer Therapeutics	4	5	2.2K
4	Gastroenterology	2	2	32
5	Pathology	2	2	187

Alison Y. Zhang

Publications

3.9K

Citations

H-Index

Page 1

	Year	Citations
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer Ian D. Davis, Andrew Martin, Martin R. Stockler, New England Journal of Medicine	2019	1.5K
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial Michael S. Hofman, Louise Emmett, Shahneen Sandhu, The Lancet UrologyOncologyGenitourinary CancerMedicineClinical Trials	2021	1K
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial James P Buteau, Andrew Martin, Louise Emmett, The Lancet Oncology Biomarker (Medicine)Prognostic BiomarkersUrologyOncologyBiomarker Analysis	2022	239
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial Christopher J. Sweeney, Andrew Martin, Martin R. Stockler, The Lancet Oncology UrologyOncologyGenitourinary CancerMedicineClinical Trials	2023	175
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study Shubham Pant, Martin Schüler, Gopa Iyer, The Lancet Oncology Fgfr AlterationsMedicinePathologyAdvanced Solid TumoursFibroblast Growth Factor	2023	175
TheraP: a randomized phase 2 trial of <sup>177</sup> Lu‐ <scp>PSMA</scp> ‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol <scp>ANZUP</scp> 1603) Michael S. Hofman, Louise Emmett, John Violet, British Journal of Urology	2019	156
Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer Seher Balaban, Zeyad D. Nassar, Alison Y. Zhang, Molecular Cancer Research	2019	86
Tissue Engineering of Lung: The Effect of Extracellular Matrix on the Differentiation of Embryonic Stem Cells to Pneumocytes Yuan‐Min Lin, Alison Y. Zhang, Helen J. Rippon, Tissue Engineering Part A	2009	74
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP Martin R. Stockler, Andrew Martin, Ian D. Davis, Journal of Clinical Oncology	2021	57
Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer Tahlia Scheinberg, Annabel Goodwin, Emilia Ip, JCO Oncology Practice	2020	49

Page 1